- Home
- PGNY vs CNTA Comparison
PGNY vs CNTA Comparison
Compare PGNY & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGNY
- CNTA
- Stock Information
- Founded
- PGNY 2008
- CNTA 2020
- Country
- PGNY United States
- CNTA United Kingdom
- Employees
- PGNY N/A
- CNTA 86
- Industry
- PGNY Misc Health and Biotechnology Services
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- PGNY Health Care
- CNTA Health Care
- Exchange
- PGNY Nasdaq
- CNTA Nasdaq
- Market Cap
- PGNY 1.8B
- CNTA 1.6B
- IPO Year
- PGNY 2019
- CNTA 2021
- Fundamental
- Price
- PGNY $20.98
- CNTA $12.43
- Analyst Decision
- PGNY Buy
- CNTA Strong Buy
- Analyst Count
- PGNY 8
- CNTA 11
- Target Price
- PGNY $22.43
- CNTA $27.00
- AVG Volume (30 Days)
- PGNY 880.6K
- CNTA 1.2M
- Earning Date
- PGNY 08-05-2025
- CNTA 08-12-2025
- Dividend Yield
- PGNY N/A
- CNTA N/A
- EPS Growth
- PGNY N/A
- CNTA N/A
- EPS
- PGNY 0.57
- CNTA N/A
- Revenue
- PGNY $1,213,181,000.00
- CNTA $15,000,000.00
- Revenue This Year
- PGNY $7.01
- CNTA N/A
- Revenue Next Year
- PGNY $11.53
- CNTA N/A
- P/E Ratio
- PGNY $36.61
- CNTA N/A
- Revenue Growth
- PGNY 9.46
- CNTA 118.88
- 52 Week Low
- PGNY $13.39
- CNTA $8.46
- 52 Week High
- PGNY $30.42
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- PGNY 43.42
- CNTA 47.36
- Support Level
- PGNY $20.70
- CNTA $11.77
- Resistance Level
- PGNY $22.16
- CNTA $13.06
- Average True Range (ATR)
- PGNY 0.73
- CNTA 0.70
- MACD
- PGNY -0.01
- CNTA 0.03
- Stochastic Oscillator
- PGNY 12.56
- CNTA 51.21
About PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.